Zelluna (7UM0) 주식 개요젤루나 ASA는 고형암 치료를 위한 T세포 수용체(TCR) 세포 면역 치료제를 개발하는 회사입니다. 자세히 보기7UM0 펀더멘털 분석스노우플레이크 점수가치 평가0/6미래 성장0/6과거 실적0/6재무 건전성6/6배당0/6위험 분석지난 1년 동안 주주가 크게 희석되었습니다.수익이 USD$1m 미만입니다(NOK8K)지난 5년간 매년 수익이 23.8% 감소했습니다.의미 있는 시가총액이 없습니다(€59M)모든 위험 점검 보기7UM0 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW480,107 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA480,107 investors already sharing narrativesYour Fair Value€Current Price€1.966.5m% 고평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-133m13m2016201920222025202620282031Revenue NOK 8.0kEarnings NOK 1.4kAdvancedSet Fair ValueView all narrativesZelluna ASA 경쟁사2investSymbol: XTRA:2INVMarket cap: €62.9mGenetic AnalysisSymbol: DB:8V8Market cap: €46.2m2investSymbol: DB:2INVMarket cap: €45.1mNovogeniaSymbol: MUN:7V0Market cap: €78.0m가격 이력 및 성과Zelluna 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가NOK 1.9652주 최고가NOK 2.9852주 최저가NOK 0.68베타01개월 변동20.31%3개월 변동-3.22%1년 변동73.93%3년 변동n/a5년 변동n/aIPO 이후 변동17.07%최근 뉴스 및 업데이트공고 • Jul 14Zelluna ASA Doses First Solid Tumour Patient with ZI-MA4-1 in the ZIMA-101 Phase 1 trialZelluna ASA announced that the first patient has been given the first dose in ZIMA-101, the Company’s first-in-human Phase 1 clinical trial evaluating ZI-MA4-1, Zelluna’s lead TCR-NK product candidate. The first patient was treated at The Christie NHS Foundation Trust in the United Kingdom, the largest single site cancer centre in Europe and the lead clinical site for the study. ZIMA-101 is evaluating ZI-MA4-1, the world's first MAGE-A4-targeting TCR-NK cell therapy to enter clinical development, in patients with advanced MAGE-A4-positive solid tumours. MAGE-A4 is present in several common cancer types, including ovarian cancer, squamous non-small cell lung cancer, synovial sarcoma and head and neck cancer. ZIMA-101 also represents the first clinical evaluation of Zelluna's proprietary TCR-NK platform and builds on years of scientific innovation, preclinical research and manufacturing development. The study is now active at two clinical sites in the United Kingdom: The Christie and The Royal Marsden NHS Foundation Trusts. Patient identification, pre-screening and screening activities continue across all four tumour indications included in the ZIMA-101 study. Zelluna expects initial clinical data from the ZIMA-101 study to emerge from mid-2026. ZIMA-101 is a first-in-human, multicentre Phase 1 dose-escalation study evaluating the safety, tolerability and preliminary anti-tumour activity of ZI-MA4-1 in patients with advanced MAGE-A4-positive solid tumours. The study is being conducted at The Christie and The Royal Marsden NHS Foundation Trusts in the United Kingdom. The study follows a dose escalation design (3+3) with three predefined dose levels and three patients per dose level. Each patient will receive three doses on Days 1, 4 and 8 of a treatment cycle. For the first patient at each dose level, an Independent Data Monitoring Committee will review the patient's data following completion of the initial safety observation period before providing recommendations on enrolment of the remaining two patients at that dose level. ZI-MA4-1 is Zelluna's lead allogeneic (off the shelf) TCR-NK product candidate and the world's first MAGE-A4-targeting TCR-NK cell therapy in clinical development. The product combines the innate tumour-killing properties of NK cells with precision tumour targeting enabled by affinity engineered T cell receptors (TCRs), with the goal of addressing key limitations of existing cell therapies in solid tumours, including scalability, tumour targeting and access.공고 • Jun 29Zelluna Activates Second Clinical Site For ZIMA-101 Phase 1 Clinical Trial Evaluating ZI-MA4-1Zelluna announced that The Royal Marsden NHS Foundation Trust has been activated as the second clinical site in the ZIMA-101 Phase 1 clinical trial evaluating ZI-MA4-1, Zelluna's lead TCR-NK product candidate. The activation of this second clinical site further expands the Company's clinical execution capabilities and patient recruitment capacity as ZIMA-101 progresses through its early stages. The site will soon be in a position to actively identify and screen patients with suitable tumour types, characteristics (including expression of the MAGE-A4 antigen and HLA-A*02 positivity) and disease stage for potential enrolment. The activation of The Royal Marsden follows the activation of the first clinical site, The Christie NHS Foundation Trust. With both sites now activated, the ZIMA-101 programme has full clinical execution capability across two of the UK's leading cancer centres. ZIMA-101 is a first-in-human Phase 1 clinical trial evaluating ZI-MA4-1, Zelluna's lead TCR-NK product candidate and the world's first MAGE-A4-targeting TCR-NK therapy in clinical development. The study marks the first clinical evaluation of Zelluna's proprietary TCR-NK platform. Zelluna remains on track for initial clinical data from the ZIMA-101 study to emerge from mid-2026.공고 • Jun 27Zelluna Reports Final Readout From Legacy Ultimovacs DOVACC Phase II Trial For UV1 Cancer VaccineZelluna announced that the NSGO-CTU sponsored Phase II DOVACC clinical trial (NCT04742075) investigating the Ultimovacs UV1 cancer vaccine, inherited through the business combination between the two companies in 2025, did not meet the primary endpoint. The investigator-led Phase II DOVACC study evaluating UV1 in BRCAwt platinum sensitive recurrent ovarian cancer did not meet its primary endpoint of progression free survival (PFS). The DOVACC readout represents the final Phase II outcome for the UV1 programme; all five Phase II studies evaluating UV1 did not meet their primary endpoints. Aside from minimal costs associated with completing the remaining study close-out activities, Zelluna does not expect to incur any further material costs related to the UV1 programme which is now considered concluded. The DOVACC trial tested the cancer vaccine UV1 in patients with BRCAwt platinum sensitive recurrent ovarian cancer. The goal was to assess whether UV1, given alongside two established cancer medicines, could slow disease progression better than standard treatment alone. The DOVACC readout represents the fifth Phase II study evaluating UV1 that has not met its primary endpoint.New Risk • Jun 21New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 44% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 24% per year over the past 5 years. Shareholders have been substantially diluted in the past year (44% increase in shares outstanding). Revenue is less than US$1m (kr8.0k revenue, or US$826). Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (€50.3m market cap, or US$57.7m).공고 • Jun 18+ 2 more updatesZelluna ASA has completed a Follow-on Equity Offering in the amount of NOK 3.163223 million.Zelluna ASA has completed a Follow-on Equity Offering in the amount of NOK 3.163223 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 170,985 Price\Range: NOK 18.5Board Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Co-Founder & Chairman Anders Tuv was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.더 많은 업데이트 보기Recent updates공고 • Jul 14Zelluna ASA Doses First Solid Tumour Patient with ZI-MA4-1 in the ZIMA-101 Phase 1 trialZelluna ASA announced that the first patient has been given the first dose in ZIMA-101, the Company’s first-in-human Phase 1 clinical trial evaluating ZI-MA4-1, Zelluna’s lead TCR-NK product candidate. The first patient was treated at The Christie NHS Foundation Trust in the United Kingdom, the largest single site cancer centre in Europe and the lead clinical site for the study. ZIMA-101 is evaluating ZI-MA4-1, the world's first MAGE-A4-targeting TCR-NK cell therapy to enter clinical development, in patients with advanced MAGE-A4-positive solid tumours. MAGE-A4 is present in several common cancer types, including ovarian cancer, squamous non-small cell lung cancer, synovial sarcoma and head and neck cancer. ZIMA-101 also represents the first clinical evaluation of Zelluna's proprietary TCR-NK platform and builds on years of scientific innovation, preclinical research and manufacturing development. The study is now active at two clinical sites in the United Kingdom: The Christie and The Royal Marsden NHS Foundation Trusts. Patient identification, pre-screening and screening activities continue across all four tumour indications included in the ZIMA-101 study. Zelluna expects initial clinical data from the ZIMA-101 study to emerge from mid-2026. ZIMA-101 is a first-in-human, multicentre Phase 1 dose-escalation study evaluating the safety, tolerability and preliminary anti-tumour activity of ZI-MA4-1 in patients with advanced MAGE-A4-positive solid tumours. The study is being conducted at The Christie and The Royal Marsden NHS Foundation Trusts in the United Kingdom. The study follows a dose escalation design (3+3) with three predefined dose levels and three patients per dose level. Each patient will receive three doses on Days 1, 4 and 8 of a treatment cycle. For the first patient at each dose level, an Independent Data Monitoring Committee will review the patient's data following completion of the initial safety observation period before providing recommendations on enrolment of the remaining two patients at that dose level. ZI-MA4-1 is Zelluna's lead allogeneic (off the shelf) TCR-NK product candidate and the world's first MAGE-A4-targeting TCR-NK cell therapy in clinical development. The product combines the innate tumour-killing properties of NK cells with precision tumour targeting enabled by affinity engineered T cell receptors (TCRs), with the goal of addressing key limitations of existing cell therapies in solid tumours, including scalability, tumour targeting and access.공고 • Jun 29Zelluna Activates Second Clinical Site For ZIMA-101 Phase 1 Clinical Trial Evaluating ZI-MA4-1Zelluna announced that The Royal Marsden NHS Foundation Trust has been activated as the second clinical site in the ZIMA-101 Phase 1 clinical trial evaluating ZI-MA4-1, Zelluna's lead TCR-NK product candidate. The activation of this second clinical site further expands the Company's clinical execution capabilities and patient recruitment capacity as ZIMA-101 progresses through its early stages. The site will soon be in a position to actively identify and screen patients with suitable tumour types, characteristics (including expression of the MAGE-A4 antigen and HLA-A*02 positivity) and disease stage for potential enrolment. The activation of The Royal Marsden follows the activation of the first clinical site, The Christie NHS Foundation Trust. With both sites now activated, the ZIMA-101 programme has full clinical execution capability across two of the UK's leading cancer centres. ZIMA-101 is a first-in-human Phase 1 clinical trial evaluating ZI-MA4-1, Zelluna's lead TCR-NK product candidate and the world's first MAGE-A4-targeting TCR-NK therapy in clinical development. The study marks the first clinical evaluation of Zelluna's proprietary TCR-NK platform. Zelluna remains on track for initial clinical data from the ZIMA-101 study to emerge from mid-2026.공고 • Jun 27Zelluna Reports Final Readout From Legacy Ultimovacs DOVACC Phase II Trial For UV1 Cancer VaccineZelluna announced that the NSGO-CTU sponsored Phase II DOVACC clinical trial (NCT04742075) investigating the Ultimovacs UV1 cancer vaccine, inherited through the business combination between the two companies in 2025, did not meet the primary endpoint. The investigator-led Phase II DOVACC study evaluating UV1 in BRCAwt platinum sensitive recurrent ovarian cancer did not meet its primary endpoint of progression free survival (PFS). The DOVACC readout represents the final Phase II outcome for the UV1 programme; all five Phase II studies evaluating UV1 did not meet their primary endpoints. Aside from minimal costs associated with completing the remaining study close-out activities, Zelluna does not expect to incur any further material costs related to the UV1 programme which is now considered concluded. The DOVACC trial tested the cancer vaccine UV1 in patients with BRCAwt platinum sensitive recurrent ovarian cancer. The goal was to assess whether UV1, given alongside two established cancer medicines, could slow disease progression better than standard treatment alone. The DOVACC readout represents the fifth Phase II study evaluating UV1 that has not met its primary endpoint.New Risk • Jun 21New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 44% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 24% per year over the past 5 years. Shareholders have been substantially diluted in the past year (44% increase in shares outstanding). Revenue is less than US$1m (kr8.0k revenue, or US$826). Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (€50.3m market cap, or US$57.7m).공고 • Jun 18+ 2 more updatesZelluna ASA has completed a Follow-on Equity Offering in the amount of NOK 3.163223 million.Zelluna ASA has completed a Follow-on Equity Offering in the amount of NOK 3.163223 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 170,985 Price\Range: NOK 18.5Board Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Co-Founder & Chairman Anders Tuv was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.공고 • Mar 27Zelluna ASA, Annual General Meeting, Apr 23, 2026Zelluna ASA, Annual General Meeting, Apr 23, 2026, at 09:00 W. Europe Standard Time.공고 • Feb 21Zelluna Receives Uk Mhra and Ethics Approval to Initiate Zima-101 First-In-Human Clinical TrialZelluna announced that the Medicines and Healthcare products Regulatory Agency (MHRA) and Research Ethics Committee (REC) has approved the Company's Clinical Trial Application (CTA) for ZIMA-101, a first-in-human Phase 1 clinical trial evaluating Zelluna-MA4-1, Zelluna's lead TCR-NK product candidate. MHRA and Ethics approvals enable Zelluna to initiate first-in-human clinical trial in the UK, marking a key milestone in the Company's transition from preclinical to clinical-stage development and representing the first clinical evaluation of its proprietary TCR-NK platform. ZIMA-101 is designed to assess the safety, tolerability, and preliminary clinical activity of ZI-MA4-1 in patients with advanced solid cancers, including lung cancer, ovarian, head and neck cancer, and sarcomas. ZIMA-1 is an off-the-shelf cell therapy that combines two powerful cancer fighting mechanisms: the precise solid tumour targeting of T cell receptors (TCRs) with the potent and broad cancer killing ability of Natural Killer (NK) cells. This approach is designed to address key limitations that have prevented existing cell therapies from working effectively in solid tumours. ZIMA4-1 targets MAGE-A4, a protein found in many solid cancers including lung, ovarian, head and neck and sarcomas. ZI-MA4- 1 has broad intellectual property coverage, including a landmark granted patent providing dominant protection for Zelluna over the entire TCR-NK field. The UK MHRA offers a well-established regulatory framework for advanced therapies, including early-phase clinical development of Advanced Therapy Medicinal Products (ATMPs), providing an efficient and supportive environment for pioneering modalities such as TCR-NK therapies. The trial will be led by Prof. Fiona Thistlethwaite at The Christie NHS Foundation Trust (Manchester, UK) with participation from Dr. Andrew Furness at The Royal Marsden (London, UK), both world leading centres for oncology and early-phase cell therapy clinical research.공고 • Feb 05Zelluna ASA Promotes Emilie Gauthy to Chief Technology OfficerZelluna ASA announced the promotion of Emilie Gauthy to Chief Technology Officer (CTO). Gauthy, who has played a central role in building Zelluna's manufacturing and CMC capabilities since joining in 2022, assumes the role with immediate effect.in her role as CTO, Gauthy will continue to lead Zelluna's manufacturing and CMC strategy as the company advances its clinical development program, scales up manufacturing capacity and expands the pipeline of its off-the-shelf TCR-NK platform. Under Gauthy's leadership, Zelluna has established a scalable manufacturing process and analytical capabilities that enabled the company to successfully submit its Clinical Trial Application (CTA) for ZI-MA4-1 to the UK MHRA in December 2025. Key achievements include locking the manufacturing process, producing and quality-testing a GMP clinical batch, and establishing the CMC foundation for the company's first-in-human clinical trial, with initial data expected to emerge from mid-2026. These achievements also enable the entire TCR-NK platform supporting the continuous development of future programs.공고 • Dec 13Zelluna Completes First Gmp Batch of Zi-Ma4-1, A Novel Tcr-Nk Cell Therapy, to Treat Patients in Upcoming First-In-Human TrialZelluna announced the successful manufacture and QC (Quality Control) testing of the first GMP (Good Manufacturing Practice) batch of its lead candidate, ZI-MA4-1. This material is intended for use in Zelluna's upcoming first-in-human clinical trial, marking a major milestone in the company's progress toward regulatory submission and patient dosing. The GMP batch was successfully produced using Zelluna's proprietary manufacturing process, which was finalised and locked in April 2025. The process is designed to deliver high-quality TCR-NK products, with the ability to generate hundreds of doses from a single manufacturing run, offering both broad patient access and cost-of-goods advantages. Zelluna remains on track to submit a CTA for ZI-MA4- 1 in 2H 2025 with initial clinical data expected mid-2026.공고 • Dec 09+ 5 more updatesZelluna ASA to Report Fiscal Year 2026 Results on Mar 31, 2027Zelluna ASA announced that they will report fiscal year 2026 results on Mar 31, 2027공고 • Nov 28Zelluna Asa Announces CFO ChangesZelluna announced the appointment of Geir Christian Melen as new Chief Financial Officer, effective 01 January 2026. Hans Vassgård Eid will be stepping down as CFO of Zelluna ASA from the end of December 2025 and supporting the transition thereafter. Geir Christian brings extensive senior leadership experience across the Norwegian biotech and life sciences sector, including multiple CFO and CEO roles in both publicly listed and privately held companies including in Algeta and Photocure. Over his career, he has led financial operations, corporate strategy, and capital market engagement for several life science organisations, giving him a deep understanding of the financial, regulatory, and operational demands of the industry.Geir Christian has also been part of Zelluna as Finance Director for over seven years, holding a key leadership role across finance and operations. He brings strong familiarity with Zelluna’s TCR-NK platform, financial strategy, and organisational priorities.공고 • Nov 04+ 2 more updatesZelluna ASA has filed a Follow-on Equity Offering in the amount of NOK 8 million.Zelluna ASA has filed a Follow-on Equity Offering in the amount of NOK 8 million. Security Name: Shares Security Type: Common Stock Securities Offered: 800,000 Price\Range: NOK 10 Transaction Features: Rights Offering공고 • Oct 10Zelluna Receives Positive MHRA Feedback and Strengthens UK Clinical Strategy for ZI-MA4-1 Paving the Way for First-In-Human Trials in the UKZelluna announced it has received positive feedback from the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) following recent scientific advice. This feedback provides alignment on the preclinical, manufacturing, clinical and regulatory pathway for ZI-MA4-1 and supports Zelluna's planned Clinical Trial Application (CTA) submission later this year. In parallel, Zelluna has advanced preparations for the first-in-human trial of ZI-MA4- 1 by engaging with leading UK cancer centres and appointing Professoriona Thistlethwaite, Medical Oncology Consultant at The Christie in Manchester, as proposed Chief Investigator. The Christie, one of Europe's leading cancer centres and a major hub for advanced cell therapy research, will serve as a lead site for the study. Both Professor Fiona Thistlethwaite at The Christie and Dr. Andrew Furness at The Royal Marsden in London, a global leader in oncology and early-phase cell therapy studies, are expected to play central roles in the trial and have contributed to shaping its design and development strategy. Subject to CTA approval, the proposed Phase I trial will be an open-label, dose-escalation basket study evaluating the safety, tolerability and preliminary efficacy of ZI-MA4 -1 across multiple solid tumours. Prof. Fiona Thistlethwaite, medical Oncology Consultant within the Experimental Cancer Medicines Team (ECMT), Clinical Lead for the Advanced Immunotherapy and Cell Therapy (AICT) Team, The Christie, and proposed Chief Investigator for the planned trial, said "I am genuinely excited to see the progress of ZI-MA 4-1 into the clinic. I am optimistic that the dual killing mechanism of the NK cells and tumour antigen directed TCR will provide with the step-change that need in the solid tumour setting to provide the required level of tumour potential whilst avoiding tumour escape".공고 • Apr 08+ 4 more updatesZelluna ASA to Report Q1, 2025 Results on May 08, 2025Zelluna ASA announced that they will report Q1, 2025 results on May 08, 2025주주 수익률7UM0DE BiotechsDE 시장7D-0.3%-0.1%0.1%1Y73.9%11.4%-0.5%전체 주주 수익률 보기수익률 대 산업: 7UM0은 지난 1년 동안 11.4%의 수익을 기록한 German Biotechs 산업보다 더 좋은 성과를 냈습니다.수익률 대 시장: 7UM0은 지난 1년 동안 -0.5%를 기록한 German 시장보다 더 좋은 성과를 냈습니다.주가 변동성Is 7UM0's price volatile compared to industry and market?7UM0 volatility7UM0 Average Weekly Movement7.3%Biotechs Industry Average Movement7.7%Market Average Movement5.3%10% most volatile stocks in DE Market12.7%10% least volatile stocks in DE Market2.7%안정적인 주가: 7UM0는 지난 3개월 동안 German 시장에 비해 주가 변동성이 크지 않았습니다.시간에 따른 변동성: 7UM0의 주간 변동성(7%)은 지난 1년 동안 안정적이었습니다.회사 소개설립직원 수CEO웹사이트201615Namir Hassanzelluna.com젤루나 ASA는 고형암 치료를 위한 T세포 수용체(TCR) 세포 면역 치료제를 개발하는 회사입니다. 이 회사는 2016년에 설립되었으며 노르웨이 오슬로에 본사를 두고 있습니다.더 보기Zelluna ASA 기초 지표 요약Zelluna의 순이익과 매출은 시가총액과 어떻게 비교됩니까?7UM0 기초 통계시가총액€58.87m순이익 (TTM)-€12.13m매출 (TTM)€731.06Over9,999x주가매출비율(P/S)-4.9x주가수익비율(P/E)7UM0는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표7UM0 손익계산서 (TTM)매출NOK 8.00k매출원가NOK 0총이익NOK 8.00k기타 비용NOK 132.74m순이익-NOK 132.73m최근 보고된 실적Mar 31, 2026다음 실적 발표일Aug 20, 2026주당순이익(EPS)-4.51총이익률100.00%순이익률-1,659,125.00%부채/자본 비율0%7UM0의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/23 00:44종가2026/07/23 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Zelluna ASA는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Geir HolomDNB Carnegie
공고 • Jul 14Zelluna ASA Doses First Solid Tumour Patient with ZI-MA4-1 in the ZIMA-101 Phase 1 trialZelluna ASA announced that the first patient has been given the first dose in ZIMA-101, the Company’s first-in-human Phase 1 clinical trial evaluating ZI-MA4-1, Zelluna’s lead TCR-NK product candidate. The first patient was treated at The Christie NHS Foundation Trust in the United Kingdom, the largest single site cancer centre in Europe and the lead clinical site for the study. ZIMA-101 is evaluating ZI-MA4-1, the world's first MAGE-A4-targeting TCR-NK cell therapy to enter clinical development, in patients with advanced MAGE-A4-positive solid tumours. MAGE-A4 is present in several common cancer types, including ovarian cancer, squamous non-small cell lung cancer, synovial sarcoma and head and neck cancer. ZIMA-101 also represents the first clinical evaluation of Zelluna's proprietary TCR-NK platform and builds on years of scientific innovation, preclinical research and manufacturing development. The study is now active at two clinical sites in the United Kingdom: The Christie and The Royal Marsden NHS Foundation Trusts. Patient identification, pre-screening and screening activities continue across all four tumour indications included in the ZIMA-101 study. Zelluna expects initial clinical data from the ZIMA-101 study to emerge from mid-2026. ZIMA-101 is a first-in-human, multicentre Phase 1 dose-escalation study evaluating the safety, tolerability and preliminary anti-tumour activity of ZI-MA4-1 in patients with advanced MAGE-A4-positive solid tumours. The study is being conducted at The Christie and The Royal Marsden NHS Foundation Trusts in the United Kingdom. The study follows a dose escalation design (3+3) with three predefined dose levels and three patients per dose level. Each patient will receive three doses on Days 1, 4 and 8 of a treatment cycle. For the first patient at each dose level, an Independent Data Monitoring Committee will review the patient's data following completion of the initial safety observation period before providing recommendations on enrolment of the remaining two patients at that dose level. ZI-MA4-1 is Zelluna's lead allogeneic (off the shelf) TCR-NK product candidate and the world's first MAGE-A4-targeting TCR-NK cell therapy in clinical development. The product combines the innate tumour-killing properties of NK cells with precision tumour targeting enabled by affinity engineered T cell receptors (TCRs), with the goal of addressing key limitations of existing cell therapies in solid tumours, including scalability, tumour targeting and access.
공고 • Jun 29Zelluna Activates Second Clinical Site For ZIMA-101 Phase 1 Clinical Trial Evaluating ZI-MA4-1Zelluna announced that The Royal Marsden NHS Foundation Trust has been activated as the second clinical site in the ZIMA-101 Phase 1 clinical trial evaluating ZI-MA4-1, Zelluna's lead TCR-NK product candidate. The activation of this second clinical site further expands the Company's clinical execution capabilities and patient recruitment capacity as ZIMA-101 progresses through its early stages. The site will soon be in a position to actively identify and screen patients with suitable tumour types, characteristics (including expression of the MAGE-A4 antigen and HLA-A*02 positivity) and disease stage for potential enrolment. The activation of The Royal Marsden follows the activation of the first clinical site, The Christie NHS Foundation Trust. With both sites now activated, the ZIMA-101 programme has full clinical execution capability across two of the UK's leading cancer centres. ZIMA-101 is a first-in-human Phase 1 clinical trial evaluating ZI-MA4-1, Zelluna's lead TCR-NK product candidate and the world's first MAGE-A4-targeting TCR-NK therapy in clinical development. The study marks the first clinical evaluation of Zelluna's proprietary TCR-NK platform. Zelluna remains on track for initial clinical data from the ZIMA-101 study to emerge from mid-2026.
공고 • Jun 27Zelluna Reports Final Readout From Legacy Ultimovacs DOVACC Phase II Trial For UV1 Cancer VaccineZelluna announced that the NSGO-CTU sponsored Phase II DOVACC clinical trial (NCT04742075) investigating the Ultimovacs UV1 cancer vaccine, inherited through the business combination between the two companies in 2025, did not meet the primary endpoint. The investigator-led Phase II DOVACC study evaluating UV1 in BRCAwt platinum sensitive recurrent ovarian cancer did not meet its primary endpoint of progression free survival (PFS). The DOVACC readout represents the final Phase II outcome for the UV1 programme; all five Phase II studies evaluating UV1 did not meet their primary endpoints. Aside from minimal costs associated with completing the remaining study close-out activities, Zelluna does not expect to incur any further material costs related to the UV1 programme which is now considered concluded. The DOVACC trial tested the cancer vaccine UV1 in patients with BRCAwt platinum sensitive recurrent ovarian cancer. The goal was to assess whether UV1, given alongside two established cancer medicines, could slow disease progression better than standard treatment alone. The DOVACC readout represents the fifth Phase II study evaluating UV1 that has not met its primary endpoint.
New Risk • Jun 21New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 44% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 24% per year over the past 5 years. Shareholders have been substantially diluted in the past year (44% increase in shares outstanding). Revenue is less than US$1m (kr8.0k revenue, or US$826). Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (€50.3m market cap, or US$57.7m).
공고 • Jun 18+ 2 more updatesZelluna ASA has completed a Follow-on Equity Offering in the amount of NOK 3.163223 million.Zelluna ASA has completed a Follow-on Equity Offering in the amount of NOK 3.163223 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 170,985 Price\Range: NOK 18.5
Board Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Co-Founder & Chairman Anders Tuv was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
공고 • Jul 14Zelluna ASA Doses First Solid Tumour Patient with ZI-MA4-1 in the ZIMA-101 Phase 1 trialZelluna ASA announced that the first patient has been given the first dose in ZIMA-101, the Company’s first-in-human Phase 1 clinical trial evaluating ZI-MA4-1, Zelluna’s lead TCR-NK product candidate. The first patient was treated at The Christie NHS Foundation Trust in the United Kingdom, the largest single site cancer centre in Europe and the lead clinical site for the study. ZIMA-101 is evaluating ZI-MA4-1, the world's first MAGE-A4-targeting TCR-NK cell therapy to enter clinical development, in patients with advanced MAGE-A4-positive solid tumours. MAGE-A4 is present in several common cancer types, including ovarian cancer, squamous non-small cell lung cancer, synovial sarcoma and head and neck cancer. ZIMA-101 also represents the first clinical evaluation of Zelluna's proprietary TCR-NK platform and builds on years of scientific innovation, preclinical research and manufacturing development. The study is now active at two clinical sites in the United Kingdom: The Christie and The Royal Marsden NHS Foundation Trusts. Patient identification, pre-screening and screening activities continue across all four tumour indications included in the ZIMA-101 study. Zelluna expects initial clinical data from the ZIMA-101 study to emerge from mid-2026. ZIMA-101 is a first-in-human, multicentre Phase 1 dose-escalation study evaluating the safety, tolerability and preliminary anti-tumour activity of ZI-MA4-1 in patients with advanced MAGE-A4-positive solid tumours. The study is being conducted at The Christie and The Royal Marsden NHS Foundation Trusts in the United Kingdom. The study follows a dose escalation design (3+3) with three predefined dose levels and three patients per dose level. Each patient will receive three doses on Days 1, 4 and 8 of a treatment cycle. For the first patient at each dose level, an Independent Data Monitoring Committee will review the patient's data following completion of the initial safety observation period before providing recommendations on enrolment of the remaining two patients at that dose level. ZI-MA4-1 is Zelluna's lead allogeneic (off the shelf) TCR-NK product candidate and the world's first MAGE-A4-targeting TCR-NK cell therapy in clinical development. The product combines the innate tumour-killing properties of NK cells with precision tumour targeting enabled by affinity engineered T cell receptors (TCRs), with the goal of addressing key limitations of existing cell therapies in solid tumours, including scalability, tumour targeting and access.
공고 • Jun 29Zelluna Activates Second Clinical Site For ZIMA-101 Phase 1 Clinical Trial Evaluating ZI-MA4-1Zelluna announced that The Royal Marsden NHS Foundation Trust has been activated as the second clinical site in the ZIMA-101 Phase 1 clinical trial evaluating ZI-MA4-1, Zelluna's lead TCR-NK product candidate. The activation of this second clinical site further expands the Company's clinical execution capabilities and patient recruitment capacity as ZIMA-101 progresses through its early stages. The site will soon be in a position to actively identify and screen patients with suitable tumour types, characteristics (including expression of the MAGE-A4 antigen and HLA-A*02 positivity) and disease stage for potential enrolment. The activation of The Royal Marsden follows the activation of the first clinical site, The Christie NHS Foundation Trust. With both sites now activated, the ZIMA-101 programme has full clinical execution capability across two of the UK's leading cancer centres. ZIMA-101 is a first-in-human Phase 1 clinical trial evaluating ZI-MA4-1, Zelluna's lead TCR-NK product candidate and the world's first MAGE-A4-targeting TCR-NK therapy in clinical development. The study marks the first clinical evaluation of Zelluna's proprietary TCR-NK platform. Zelluna remains on track for initial clinical data from the ZIMA-101 study to emerge from mid-2026.
공고 • Jun 27Zelluna Reports Final Readout From Legacy Ultimovacs DOVACC Phase II Trial For UV1 Cancer VaccineZelluna announced that the NSGO-CTU sponsored Phase II DOVACC clinical trial (NCT04742075) investigating the Ultimovacs UV1 cancer vaccine, inherited through the business combination between the two companies in 2025, did not meet the primary endpoint. The investigator-led Phase II DOVACC study evaluating UV1 in BRCAwt platinum sensitive recurrent ovarian cancer did not meet its primary endpoint of progression free survival (PFS). The DOVACC readout represents the final Phase II outcome for the UV1 programme; all five Phase II studies evaluating UV1 did not meet their primary endpoints. Aside from minimal costs associated with completing the remaining study close-out activities, Zelluna does not expect to incur any further material costs related to the UV1 programme which is now considered concluded. The DOVACC trial tested the cancer vaccine UV1 in patients with BRCAwt platinum sensitive recurrent ovarian cancer. The goal was to assess whether UV1, given alongside two established cancer medicines, could slow disease progression better than standard treatment alone. The DOVACC readout represents the fifth Phase II study evaluating UV1 that has not met its primary endpoint.
New Risk • Jun 21New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 44% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 24% per year over the past 5 years. Shareholders have been substantially diluted in the past year (44% increase in shares outstanding). Revenue is less than US$1m (kr8.0k revenue, or US$826). Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (€50.3m market cap, or US$57.7m).
공고 • Jun 18+ 2 more updatesZelluna ASA has completed a Follow-on Equity Offering in the amount of NOK 3.163223 million.Zelluna ASA has completed a Follow-on Equity Offering in the amount of NOK 3.163223 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 170,985 Price\Range: NOK 18.5
Board Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Co-Founder & Chairman Anders Tuv was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
공고 • Mar 27Zelluna ASA, Annual General Meeting, Apr 23, 2026Zelluna ASA, Annual General Meeting, Apr 23, 2026, at 09:00 W. Europe Standard Time.
공고 • Feb 21Zelluna Receives Uk Mhra and Ethics Approval to Initiate Zima-101 First-In-Human Clinical TrialZelluna announced that the Medicines and Healthcare products Regulatory Agency (MHRA) and Research Ethics Committee (REC) has approved the Company's Clinical Trial Application (CTA) for ZIMA-101, a first-in-human Phase 1 clinical trial evaluating Zelluna-MA4-1, Zelluna's lead TCR-NK product candidate. MHRA and Ethics approvals enable Zelluna to initiate first-in-human clinical trial in the UK, marking a key milestone in the Company's transition from preclinical to clinical-stage development and representing the first clinical evaluation of its proprietary TCR-NK platform. ZIMA-101 is designed to assess the safety, tolerability, and preliminary clinical activity of ZI-MA4-1 in patients with advanced solid cancers, including lung cancer, ovarian, head and neck cancer, and sarcomas. ZIMA-1 is an off-the-shelf cell therapy that combines two powerful cancer fighting mechanisms: the precise solid tumour targeting of T cell receptors (TCRs) with the potent and broad cancer killing ability of Natural Killer (NK) cells. This approach is designed to address key limitations that have prevented existing cell therapies from working effectively in solid tumours. ZIMA4-1 targets MAGE-A4, a protein found in many solid cancers including lung, ovarian, head and neck and sarcomas. ZI-MA4- 1 has broad intellectual property coverage, including a landmark granted patent providing dominant protection for Zelluna over the entire TCR-NK field. The UK MHRA offers a well-established regulatory framework for advanced therapies, including early-phase clinical development of Advanced Therapy Medicinal Products (ATMPs), providing an efficient and supportive environment for pioneering modalities such as TCR-NK therapies. The trial will be led by Prof. Fiona Thistlethwaite at The Christie NHS Foundation Trust (Manchester, UK) with participation from Dr. Andrew Furness at The Royal Marsden (London, UK), both world leading centres for oncology and early-phase cell therapy clinical research.
공고 • Feb 05Zelluna ASA Promotes Emilie Gauthy to Chief Technology OfficerZelluna ASA announced the promotion of Emilie Gauthy to Chief Technology Officer (CTO). Gauthy, who has played a central role in building Zelluna's manufacturing and CMC capabilities since joining in 2022, assumes the role with immediate effect.in her role as CTO, Gauthy will continue to lead Zelluna's manufacturing and CMC strategy as the company advances its clinical development program, scales up manufacturing capacity and expands the pipeline of its off-the-shelf TCR-NK platform. Under Gauthy's leadership, Zelluna has established a scalable manufacturing process and analytical capabilities that enabled the company to successfully submit its Clinical Trial Application (CTA) for ZI-MA4-1 to the UK MHRA in December 2025. Key achievements include locking the manufacturing process, producing and quality-testing a GMP clinical batch, and establishing the CMC foundation for the company's first-in-human clinical trial, with initial data expected to emerge from mid-2026. These achievements also enable the entire TCR-NK platform supporting the continuous development of future programs.
공고 • Dec 13Zelluna Completes First Gmp Batch of Zi-Ma4-1, A Novel Tcr-Nk Cell Therapy, to Treat Patients in Upcoming First-In-Human TrialZelluna announced the successful manufacture and QC (Quality Control) testing of the first GMP (Good Manufacturing Practice) batch of its lead candidate, ZI-MA4-1. This material is intended for use in Zelluna's upcoming first-in-human clinical trial, marking a major milestone in the company's progress toward regulatory submission and patient dosing. The GMP batch was successfully produced using Zelluna's proprietary manufacturing process, which was finalised and locked in April 2025. The process is designed to deliver high-quality TCR-NK products, with the ability to generate hundreds of doses from a single manufacturing run, offering both broad patient access and cost-of-goods advantages. Zelluna remains on track to submit a CTA for ZI-MA4- 1 in 2H 2025 with initial clinical data expected mid-2026.
공고 • Dec 09+ 5 more updatesZelluna ASA to Report Fiscal Year 2026 Results on Mar 31, 2027Zelluna ASA announced that they will report fiscal year 2026 results on Mar 31, 2027
공고 • Nov 28Zelluna Asa Announces CFO ChangesZelluna announced the appointment of Geir Christian Melen as new Chief Financial Officer, effective 01 January 2026. Hans Vassgård Eid will be stepping down as CFO of Zelluna ASA from the end of December 2025 and supporting the transition thereafter. Geir Christian brings extensive senior leadership experience across the Norwegian biotech and life sciences sector, including multiple CFO and CEO roles in both publicly listed and privately held companies including in Algeta and Photocure. Over his career, he has led financial operations, corporate strategy, and capital market engagement for several life science organisations, giving him a deep understanding of the financial, regulatory, and operational demands of the industry.Geir Christian has also been part of Zelluna as Finance Director for over seven years, holding a key leadership role across finance and operations. He brings strong familiarity with Zelluna’s TCR-NK platform, financial strategy, and organisational priorities.
공고 • Nov 04+ 2 more updatesZelluna ASA has filed a Follow-on Equity Offering in the amount of NOK 8 million.Zelluna ASA has filed a Follow-on Equity Offering in the amount of NOK 8 million. Security Name: Shares Security Type: Common Stock Securities Offered: 800,000 Price\Range: NOK 10 Transaction Features: Rights Offering
공고 • Oct 10Zelluna Receives Positive MHRA Feedback and Strengthens UK Clinical Strategy for ZI-MA4-1 Paving the Way for First-In-Human Trials in the UKZelluna announced it has received positive feedback from the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) following recent scientific advice. This feedback provides alignment on the preclinical, manufacturing, clinical and regulatory pathway for ZI-MA4-1 and supports Zelluna's planned Clinical Trial Application (CTA) submission later this year. In parallel, Zelluna has advanced preparations for the first-in-human trial of ZI-MA4- 1 by engaging with leading UK cancer centres and appointing Professoriona Thistlethwaite, Medical Oncology Consultant at The Christie in Manchester, as proposed Chief Investigator. The Christie, one of Europe's leading cancer centres and a major hub for advanced cell therapy research, will serve as a lead site for the study. Both Professor Fiona Thistlethwaite at The Christie and Dr. Andrew Furness at The Royal Marsden in London, a global leader in oncology and early-phase cell therapy studies, are expected to play central roles in the trial and have contributed to shaping its design and development strategy. Subject to CTA approval, the proposed Phase I trial will be an open-label, dose-escalation basket study evaluating the safety, tolerability and preliminary efficacy of ZI-MA4 -1 across multiple solid tumours. Prof. Fiona Thistlethwaite, medical Oncology Consultant within the Experimental Cancer Medicines Team (ECMT), Clinical Lead for the Advanced Immunotherapy and Cell Therapy (AICT) Team, The Christie, and proposed Chief Investigator for the planned trial, said "I am genuinely excited to see the progress of ZI-MA 4-1 into the clinic. I am optimistic that the dual killing mechanism of the NK cells and tumour antigen directed TCR will provide with the step-change that need in the solid tumour setting to provide the required level of tumour potential whilst avoiding tumour escape".
공고 • Apr 08+ 4 more updatesZelluna ASA to Report Q1, 2025 Results on May 08, 2025Zelluna ASA announced that they will report Q1, 2025 results on May 08, 2025
